Vanda (VNDA) Q2 FY26 earnings call

Vanda Pharmaceuticals reported strong Q2 FY26 performance, primarily driven by FENAPT's continued growth and the commercial launch of Nereus, alongside significant pipeline advancements including Bisanti's approval and Quimilza's upcoming PDUFA date. Despite increased operating expenses for pipeline development and commercialization efforts, the company anticipates expenses to moderate by year-end 2026 and into 2027, with current resources projected to fund operations through at least the end of 2027.